Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
Launched by RUSH UNIVERSITY MEDICAL CENTER · Nov 17, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to treat a specific heart condition called ventricular tachycardia (VT) in patients who have ischemic cardiomyopathy, a type of heart disease caused by reduced blood flow to the heart. The study will test whether using a technique called Ablation Index (AI) can improve the results of a procedure known as radiofrequency catheter ablation (RFCA), which helps to stop dangerous heart rhythms. The goal is to see if this AI-guided approach can make the procedure faster and more effective for patients with scar tissue in their hearts from previous heart damage.
To participate in the trial, individuals must be at least 18 years old and have a diagnosis of ischemic cardiomyopathy along with a history of sustained scar-related VT, which means their heart has been showing this dangerous rhythm on tests. However, those who have had recent heart issues, such as a heart attack or major surgery, or other specific conditions may not be eligible. Participants in the trial can expect to undergo the RFCA procedure while researchers carefully monitor the outcomes to gather important data on the safety and effectiveness of the AI-guided method. This study aims to provide new insights into treating this serious heart condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient ≥ 18 y.o.
- • Structural Heart Disease: Ischemic Cardiomyopathy
- • Sustained Scar-related Monomorphic Ventricular Tachycardia documented by ECG or CIED interrogation
- Exclusion Criteria:
- • If clinical ventricular arrhythmia is predominantly PVCs, supraventricular tachycardia, or ventricular fibrillation
- • Myocardial infarction or cardiac surgery within 6 months
- • Severe mitral regurgitation
- • Stroke or TIA within 6 months
- • Prior VT substrate ablation in the previous 6 months
- • NYHA functional class IV
- • Non-ischemic VT substrate
About Rush University Medical Center
Rush University Medical Center is a leading academic medical institution located in Chicago, Illinois, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of numerous clinical studies, Rush focuses on translating scientific discoveries into effective treatments and improving patient outcomes across a variety of medical disciplines. With a commitment to excellence in patient care, education, and research, Rush leverages its state-of-the-art facilities and a robust network of specialists to conduct comprehensive trials that adhere to the highest ethical and regulatory standards. Through collaboration with a diverse patient population, Rush aims to enhance the understanding of diseases and develop novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Charleston, South Carolina, United States
Cleveland, Ohio, United States
Cleveland, Ohio, United States
Chicago, Illinois, United States
Ann Arbor, Michigan, United States
Boston, Massachusetts, United States
Patients applied
Trial Officials
Henry Huang, MD
Principal Investigator
Henry_D_Huang@rush.edu
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported